Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2017

View Archived Issues

Gene-corrected hematopoietic stem-progenitor cells to treat infantile neuronal ceroid lipofuscinosis

FDA grants orphan drug designation to RASRx-1902 for Duchenne muscular dystrophy

Scripps Research Institute announces USD 7 million grant to develop new therapies for ALS

Recordati licenses neurotrophic keratitis candidate from MimeTech

Boehringer Ingelheim presents first-in-human results for BI-894999

Bristol-Myers Squibb TYK2 inhibitor BMS-986165 promising in phase I trial

Human pluripotent stem cells used for cartilage repair in animal models

ALRN-6924 demonstrates clinical antitumor activity across a variety of wild-type TP53 tumors

Topline data update for phase III clinical study of hGH-CTP in adults with growth hormone deficiency

Phase III trial of anlotinib as third-line treatment for NSCLC meets primary endpoint

Abide Therapeutics divulges novel MGL/FAAH inhibitors

Selecta Biosciences announces data from phase II study of SEL-212 for gout

Novel LRRK2 inhibitors patented by Denali Therapeutics

Janssen R&D Ireland synthesizes new anti-influenza compounds

Taiho Pharmaceutical patents KDM1A inhibitors

Basilea Pharmaceutica presents new bacterial efflux pump inhibitors

Immunocore and Adaptimmune describe novel SLC45A2-derived peptides

NIA selects CDX-085 for its anti-aging Interventions Testing Program

FDA expands approved use of Ipsen's Dysport

New phase IIa study evaluates OPB-111077 in advanced refractory cancers

Agilent announces expanded use of PD-L1 IHC 28-8 pharmDx test

Incyte initiates phase I study of INCB-062079 in HCC and other malignancies

Novartis presents data for the novel antibacterial agent LYS-228

Genmab reports data from cervical cancer cohort of phase I/II study of tisotumab vedotin

GamLPV vaccine for prevention of whooping cough studied in new phase I trial

Seikagaku initiates phase II study in U.S. with SI-613 for knee osteoarthritis

Intrexon completes acquisition of GenVec

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...